Simone Feresin, Ophthalmology Lead Roche Ireland (Products) Ltd, on finding solutions for the leading causes of vision loss
Globally, at least 2.2 billion people have a near or distance vision impairment. In at least half of these cases, vision impairment could have
been prevented or has yet to be addressed. At Roche, we’re dedicated to finding solutions for the leading causes of vision loss using innovative medicines, ground-breaking technology, and artificial intelligence (AI).
Our focus is on the discovery and development of transformational solutions for people with potentially blinding retinal conditions. Some of these conditions are incredibly common and may lead to permanent vision loss. This is a great unmet medical need that, if successfully addressed, could bring meaningful benefit to the lives of many people.
Advanced analytics offer new insights Retinal conditions vary for each individual and as a result, can be difficult to treat. This is why we’re investing in personalised healthcare (PHC) in Ophthalmology. When it comes to PHC and ophthalmology, our overarching strategy is to use advanced analytics to gain new insights from advanced imaging (e.g. optical coherence tomography) derived from our vast databases of retinal images.
Beyond that, molecular profiles of ocular fluid, as well as clinical and genomic data, also enable us to drive PHC in ophthalmology. We’re also exploring the potential to develop pilot AI and Machine Learning tools that can sift through massive datasets to predict responses to treatment and the risk of disease progression.
The information yielded by diverse analytic tools may improve our ability to develop better treatments and help ophthalmologists deliver the right dose and treatment regimen to people. I like to think of our PHC approach in ophthalmology as having a two-way benefit: both in clinical development and clinical decision-making support. We’re in a unique position at Roche to use our knowledge to advance care and access for Ophthalmology patients.
Our aim is to bring personalised healthcare to patients and I’m very excited to see what our future innovations might yield.